Update on CARES Phase III Clinical Program of Anselamimab in Light Chain Amyloidosis
July 17, 2025
July 17, 2025
WILMINGTON, Delaware, July 17 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Update on CARES Phase III clinical program of anselamimab in light chain amyloidosis
Results did not achieve statistical significance for the primary endpoint in overall patient population
Anselamimab showed highly clinically meaningful improvement vs. placebo in survival and cardiovascular hospitalization in prespecified patient . . .
* * *
Update on CARES Phase III clinical program of anselamimab in light chain amyloidosis
Results did not achieve statistical significance for the primary endpoint in overall patient population
Anselamimab showed highly clinically meaningful improvement vs. placebo in survival and cardiovascular hospitalization in prespecified patient . . .